Myriad Proteomics of Salt Lake City and its new CEO Thomas Ingolia have jumped on the drug discovery bandwagon — and are now riding it full speed. Armed with an array of new and established technologies, most notably a target pull-down approach known as chemiproteomics, Myriad has abandoned its quest to map the entire human proteome and now hopes to carve out a niche in the increasingly crowded field of collaborative target validation and discovery.

Get the full story with GenomeWeb Premium

Only $95 for the first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.